RxDoctor Payments Data

Matthew Donovan, MD

Ophthalmology · Clearwater, FLNPI 1366804858

Payments from drug & device makers

$15,075in general payments, 2019–2025

Across 75 payments — averaging $201.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coherus Oncology, Inc.$10K
  • Apellis Pharmaceuticals, Inc.$3K
  • Regeneron Healthcare Solutions, Inc.$648
  • Genentech USA, Inc.$332
  • Notal Vision, Inc.$227
  • Astellas Pharma US Inc$161
  • plus $662 from 10 others

What the payments were for

  • Consulting fees$2,16414%
  • Speaking & faculty fees$9,11460%
  • Travel & lodging$1,0307%
  • Food & beverage$2,75318%
  • Education$150%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,075 in reported general payments places this provider in the 85th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$1,778,830
Medicare patients
1,265
Services billed
37,080

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost11$6,366
Prednisolone Acetate117$4,370
Ketorolac Tromethamine113$2,965
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat56$911
Latanoprost63$670
Brimonidine Tartrate36$565
Timolol Maleate24$189

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan$123$6,36611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Clearwater

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →